Administrative Core

$284,540P50FY2013CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Linked publications & trials

Paper 39663641 Paper 39120256 Paper 38894678 Paper 38687617 Paper 38182874 Paper 37689063 Paper 37663929 Paper 37558833 Paper 37249585 Paper 36909640 Paper 36622276 Paper 36413141 Paper 36125519 Paper 36125434 Paper 36103646 Paper 35836303 Paper 35695870 Paper 35584006 Paper 35523889 Paper 35254710 Paper 35201849 Paper 35131873 Paper 35121110 Paper 35105671 Paper 35031563 Paper 34939926 Paper 34911936 Paper 34880124 Paper 34496240 Paper 34256096 Paper 34168052 Paper 33956343 Paper 33888356 Paper 33863813 Paper 33860950 Paper 33849963 Paper 33627383 Paper 33500320 Paper 33168599 Paper 33086052 Paper 33062306 Paper 32913135 Paper 32624279 Paper 32556091 Paper 32484436 Paper 32478682 Paper 32164144 Paper 32127465 Paper 31912798 Paper 31754047 Paper 31676563 Paper 31591549 Paper 31554818 Paper 31525487 Paper 31363002 Paper 31318977 Paper 31179538 Paper 31155658 Paper 31101725 Paper 31095304 Paper 31085648 Paper 31061129 Paper 30894499 Paper 30893145 Paper 30890759 Paper 30867220 Paper 30811282 Paper 30773341 Paper 30602500 Paper 30578319 Paper 30537509 Paper 30500466 Paper 30496346 Paper 30469014 Paper 30427533 Paper 30420441 Paper 30385733 Paper 30382943 Paper 30333152 Paper 30327313 Paper 30302603 Paper 30301696 Paper 30242839 Paper 30242112 Paper 30237027 Paper 30224544 Paper 30217568 Paper 30165429 Paper 30141208 Paper 30108097 Paper 30082473 Paper 30021909 Paper 30012673 Paper 30009541 Paper 29921690 Paper 29915914 Paper 29882250 Paper 29786791 Paper 29707790 Paper 29263420

Abstract

This application represents a renewal application for a Specialized Program of Research Excellence (SPORE) in Prostate Cancer from the Prostate Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Prostate Cancer SPORE has been continuously funded since 2002. DF/HCC is comprised of the following institutions: Dana-Farber Cancer Institute; Harvard Medical School; Harvard School of Public Health; Beth Israel-Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; and Children's Hospital of Boston. In addition to the institutions in the DF/HCC, the Broad Institute is a collaborating institution in this grant. The DF/HCC Prostate Cancer SPORE has its administrative base at the DFCI. Dr. Philip Kantoff, who has led the DF/HCC Prostate Cancer Program and SPORE since their inception, is joined by Co-Directors Dr. William Hahn, a laboratory scientist at DFCI, and Dr. Steven Balk, a laboratory scientist at BIDMC. Dr. Kantoff reports directly to Dr. Edward Benz, Director of DF/HCC and President of DFCI. The DF/HCC Prostate Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 5 Projects which address critical problems in prostate cancer and have translational components including 1) understanding the mechanism by which obesity impacts prostate cancer mortality 2) dissecting the clinical heterogeneity of Gleason 7 prostate cancer 3) elucidating the importance of the EZH2 signaling pathway 4) understanding the role that genomic change has on resistance to androgen deprivation therapy and on aggressive prostate cancer and finally 5) understanding the mechanism that underlie resistance to secondary forms of hormonal therapy. The five projects are supported by three Cores, an Administrative, a Biostatistics and Computional Biology and a Tissue and Pathology Core. We also have a highly successful Career Development Progam that selects talented phycian scientists and mentors them to independence and a Developmental Projects Program that generates new ideas for the SPORE in the future.

View original record on NIH RePORTER →